Indiana Autism Therapy Provider Drew $29 Million from Medicaid for 84 Children, Raising Oversight Questions

A Surge in Autism Spending

Indiana’s Medicaid program paid $29 million in 2023 to one autism therapy provider that treated just 84 children, averaging roughly $340,000 per patient. The payments, which far exceeded the cost of a year of nursing-home care or many cancer treatments, have captured the attention of state and federal health officials amid a national boom in spending on autism services.

The Indiana provider charged as much as $640 per hour for therapy sessions—more than ten times the national average hourly rate—and became one of Medicaid’s highest-paid behavioral health contractors. Much of the therapy was delivered by staff with minimal formal education, often high school graduates working under supervision from higher-credentialed analysts. While the company saw its billings soar, its owner reportedly purchased multiple high-end properties, including a $2.5 million home on Florida’s Sanibel Island and a $600,000 house on a waterfront site in Indiana.

In response, Indiana officials have since made adjustments to reimbursement structures, hoping to bring costs in line with national standards.

The Rapid Growth of Medicaid Autism Expenditures

The Indiana case reflects a broader national trend. Medicaid payments for autism therapy, particularly for Applied Behavior Analysis (ABA) services, have skyrocketed over the past several years. Nationwide, direct state and federal spending on ABA climbed from $660 million in 2019 to $2.2 billion in 2023, making it one of the fastest-growing categories of Medicaid-funded care.

Federal taxpayers covered roughly 70 percent of that total cost, as Medicaid’s joint federal-state structure means Washington shoulders the majority of program expenses. The shift highlights how rapidly autism treatment has become a dominant expenditure within child-focused behavioral health.

During the same five-year stretch, the number of companies offering ABA therapy nearly doubled. Many of these new entrants are backed by private investors who view the expanding market—and often limited oversight—as an opportunity for profit.

Understanding Applied Behavior Analysis

Applied Behavior Analysis is currently the most widely prescribed therapy for children diagnosed with autism spectrum disorder. It focuses on teaching language and communication, improving social interaction, and reinforcing adaptive behaviors. ABA typically involves structured sessions in which therapists guide children through repetitive tasks, recording their responses and adjusting lessons over time.

Most of the day-to-day work is performed by entry-level technicians—often earning less than $20 an hour—under the supervision of a certified behavior analyst with a master’s degree or higher. The national average reimbursement to providers stood at about $61 per hour in 2023.

While research supports ABA’s effectiveness for some children, experts have long debated the appropriate intensity and duration of therapy. Some clinicians recommend as many as 40 hours per week, but others caution that such levels can be excessive, especially for very young children. The lack of universally accepted clinical guidelines leaves states vulnerable to overbilling and inconsistent outcomes.

State-by-State Disparities

The Medicaid data show that therapy intensity varied widely across states. The national average approached 14 hours per week per patient in 2023, but some providers in Indiana, Minnesota, Colorado, and Florida routinely billed for more than double that amount—30 hours or more per week, per child.

In Colorado, for example, one large private-equity-backed provider billed an average of 33 hours weekly for each patient, drawing more than $18 million from the state’s Medicaid program that year. According to oversight records, more than 75 percent of its patients were recorded as receiving full-time therapy in at least one week—a rate far above clinical norms.

Indiana’s leading provider similarly reported sustained high-volume billing. Even after adjustments made by the state, its cumulative reimbursement remained among the highest in the nation relative to the number of children served.

Red Flags from Federal Auditors

Federal oversight efforts have identified widespread compliance concerns across multiple states. Audits of claim samples from Indiana, Colorado, Wisconsin, and Maine found that every file reviewed contained at least one billing violation.

Common issues included charges for therapy sessions conducted while children were napping or watching television—activities that do not count as treatment under Medicaid’s rules. One auditor reportedly questioned whether the programs were “charging Medicaid for movie time,” reflecting frustration over gray areas in how therapy activities are documented.

Such findings point to a fundamental challenge: Medicaid’s decentralized administration allows states substantial discretion in determining what qualifies as reimbursable therapy. Without standardized definitions or strong verification systems, billing errors—and, in some cases, fraud—become difficult to prevent.

Criminal Allegations and Fraud Investigations

The tension between expanding services and enforcing accountability is no longer academic. In Minnesota, prosecutors filed criminal charges against two ABA providers accused of paying kickbacks to parents and billing Medicaid for therapy that was never delivered. Together, the two operations allegedly collected about $20 million before being shut down. The cases were part of a broader inquiry into misuse of social-service funds in the state.

While not every irregularity rises to the level of fraud, officials warn that the combination of high reimbursement rates, weak standards, and rapid industry growth creates fertile conditions for abuse. As one Medicaid compliance director explained, “When you have rates this high and documentation this loose, every incentive points in the wrong direction.”

Evidence Gaps and Policy Dilemmas

Part of the problem stems from a lack of clear, evidence-based recommendations on how much therapy is most beneficial. Applied Behavior Analysis proponents often cite studies showing improved developmental outcomes with higher frequencies of sessions. Yet those studies are based on small sample sizes and may not reflect the diversity of children currently receiving care.

Without firm clinical limits, some states find it politically and ethically difficult to deny reimbursement when providers claim that intensive therapy is medically necessary. The result is substantial variability from one state to another—not just in spending, but also in definitions of “appropriate care.”

For instance, Indiana’s 2023 expenditure per child dwarfed the national average. Meanwhile, several states, including Oregon and New York, set explicit caps on weekly therapy hours in their Medicaid guidelines to balance access with affordability. These differences underscore the broader policy dilemma facing Medicaid administrators: how to encourage treatment access for children with autism without enabling unchecked cost escalation.

The Economic Impact of Rising Autism Costs

Financially, the soaring Medicaid expenditures for autism therapy carry implications beyond the health sector. Because federal matching funds cover a majority of the costs, states can be tempted to expand programs aggressively, knowing much of the bill is paid by Washington. Yet those same states must eventually contend with the fiscal consequences of medical inflation within their own budgets.

At the national level, the leap from $660 million in 2019 to $2.2 billion in 2023 represents an annual spending growth rate of roughly 35 percent—far outpacing inflation and enrollment trends. If growth continues at that pace, autism therapy could consume more Medicaid resources than some long-established programs, including substance-abuse treatment and certain forms of home health care.

State budget officers warn that such rapid expansion will strain future budgets, particularly if federal funding formulas change or if audit findings trigger repayment demands.

Comparing with Past Healthcare Spending Surges

Historically, Medicaid’s most dramatic cost increases have come from expanding coverage of new medical technologies or novel pharmaceuticals. The autism therapy surge marks a departure: a behavioral service driving expenditure growth without a corresponding technological breakthrough.

Similar patterns have appeared before. In the early 2000s, for instance, Medicaid costs spiked when home health agencies and mental-health rehabilitation programs expanded faster than state regulators could monitor. Many of those initiatives later required scaled-back reimbursement rates after fraud and overbilling scandals emerged. Observers fear a similar correction may loom for autism therapy unless stricter oversight frameworks are introduced.

Moves Toward Reform

Following the Indiana revelations, officials moved to revise some payment formulas, particularly those tied to hourly rates and supervision ratios. Proposed rule changes would limit reimbursement for lower-credentialed staff and establish clearer documentation requirements. Indiana is also evaluating whether to cap total annual therapy hours per child, aligning its standards more closely with other states.

Nationally, Medicaid administrators are discussing the creation of a centralized data system to track utilization and flag anomalies in real time. Advocates of reform say such transparency could distinguish legitimate therapy providers from those exploiting regulatory gaps.

Meanwhile, parents of children receiving ABA therapy face their own dilemma: balancing concern over program integrity with the desire to maintain access to a service that, for many families, remains the only structured form of support available.

Outlook: Balancing Access and Accountability

The Indiana case has intensified debate over how Medicaid can sustain both fiscal accountability and compassionate care. With autism diagnoses among 8-year-olds reaching one in 31 by 2022—up from one in 150 in 2000—the demand for early intervention is expected to continue rising. Policymakers and health agencies now face pressure to design systems that ensure every dollar spent translates into meaningful outcomes for children rather than excess profit for companies.

As states reassess their policies, the balance between access and oversight will likely define the next chapter in Medicaid’s evolving role as the nation’s largest funder of autism therapy. Whether recent reforms can restrain spending without curbing essential services remains an open—and increasingly urgent—question.